A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy
This Study is
No Longer Enrolling
Adult
Must be 18-75 years of age History of Psoriatic Arthritis of 6 months or more Have active Psoriatic Arthritis with 3 or more swollen joints and 3 or more tender joints Have a Serum CRP equal or greater than 6
III - Research Studies that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.
Treatment
Barbara Davis Center
University of Colorado Hospital
Protocol Number: 19-2533
More information available at ClinicalTrials.gov: NCT04115748
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers